ArticleSubstance abuse treatment, prevention, and policy2020
A double-edged sword of using opioids and COVID-19: a toxicological view.
Article in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis.Addiction science & clinical practice · 2022Pooled it
- Opioid usage and COVID-19 prognosis: A systematic review and meta-analysis.The American journal of emergency medicine · 2022Pooled it
- Investigating the role of opium consumption in the severity, and outcome of COVID-19.BMC infectious diseases · 2026Article
- Statistical methods for assessing drug interactions using observational data.Journal of applied statistics · 2024Article
- Association between opioid abuse and COVID-19 susceptibility: a propensity score matched study.BMC infectious diseases · 2023Article
- Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023Review
- Review
- Increasing opium use in Iran in response to unsubstantiated rumors that it protects against COVID-19.Addiction (Abingdon, England) · 2022Article
- Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.European journal of medical research · 2022Review
- Opioid-Use, COVID-19 Infection, and Their Neurological Implications.Frontiers in neurology · 2022Review
- From acute SARS-CoV-2 infection to pulmonary hypertension.Frontiers in physiology · 2022Review
- Maintaining treatment and prevention programs for opioid use disorders during the coronavirus disease 2019 pandemic.Current opinion in psychiatry · 2021Review
- Genetic correlations between COVID-19 and a variety of traits and diseases.Innovation (Cambridge (Mass.)) · 2021Article
- The Reasons for Higher Mortality Rate in Opium Addicted Patients with COVID-19: A Narrative Review.Iranian journal of public health · 2021Review
- Opioids in COVID-19: Two Sides of a Coin.Frontiers in pharmacology · 2021Review
- Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, COVID-19 is spreading around the world. Information about its mechanism, prognostic factors, and management is minimal. COVID-19, as a human disease, has several identifying phases. Physicians of patients with COVID-19 may be interested in knowing whether opioid use disorder may affect their patients' course or prognosis. This information may be crucial when considering the opioid epidemic in the US and other parts of the world. Opioid use at high doses and over several months duration can mitigate the immune system's function, which may complicate the course of COVID-19 disease. Potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications in various phases of the COVID-19. Specifically, opioid use disorders via an inhalation route may enhance the "late hyper-inflammatory phase" or result in end-organ damage. It is well established that opioids decrease ventilation as their effect on the medullary respiratory centers increases the risk of pneumonia. This increased risk has been associated with immune-suppressive opioids. The ultimate role of opioids in COVID-19 is not clear. This paper endorses the need for clinical studies to decipher the role and impact of chronic opioid use on viral diseases such as COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.